Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance

• DOI: 10.1186/s12935-024-03280-x
• Publication Date: 2024-03-10T14:01:17Z
• Authors: Wanxian Chen; Deyi Geng; Jiasheng Chen; Xiaosha Han; Qihu Xie; Genghong Guo; Xuefen Chen; Wancong Zhang; Shijie Tang; Xiaoping Zhong
• Keywords: Targeted Therapy

Abstract Background Despite advances in therapeutic strategies, resistance to immunotherapy and the off-target effects of targeted therapy have significantly weakened benefits for patients with melanoma. Main body Alternative splicing plays a crucial role transcriptional reprogramming during melanoma development. In particular, aberrant alternative is involved efficacy immunotherapy, therapy, metastasis. Abnormal expression factors variants may serve as biomarkers or targets diagnosis prognosis Therefore, comprehensively integrating their roles related mechanisms essential. This review provides first detailed summary process changes occurring this pathway. Conclusion The focus provide strategies developing novel diagnostic summarize potential alter therapies immunotherapy.